We’re working to bring a first-in-class Autism treatment to market. We believe this treatment has the potential to affect both core and non-core symptoms in children with Autism. Take a closer look at what we’ve discovered, and learn more about our novel approach.
LEARN MORE
5.4 million children in the U.S., aged 4-17 years old (or 3-9% of school aged population) have been diagnosed with Attention-Deficit Hyperactivity Disorder (ADHD)—characterized by inattention, hyperactivity and impulsivity.
LEARN MORE
Our drug candidate, CM-1212, seeks to treat alcohol and drug addiction. Individuals addicted to drugs and alcohol lack the ability to properly digest and absorb essential nutrients. Emerging research indicates a role for amino acids in the persistence of addictive behaviors.
LEARN MORE
Although no cure exists for Parkinson’s disease (PD), various medications, surgeries, and physical therapies can help improve symptoms and reduce the disease’s progression.
Our drug candidate, CM-PK, may be able to affect dopamine levels in PD patients while also improving postural instability and reducing falls.
LEARN MORE
The current treatment for schizophrenia, antipsychotics, can lead to numerous side effects, including drowsiness, dizziness, and rapid heartbeat.
We are developing an enzyme replacement therapy, CM-182, that may be helpful in the treatment of schizophrenia. Animal model studies of CM-182 have shown effectiveness in treating the positive symptoms of schizophrenia without sedation.
LEARN MORECuremark has built a broad product pipeline that addresses an array of disorders.
The company’s lead asset, CM-AT, is an orally-delivered treatment for Autism Spectrum Disorder (ASD). CM-AT is designed to treat the maladaptive behaviors of irritability, agitation, hyperactivity, non-compliance and inappropriate speech in children with Autism as young as age 3. The Phase III, placebo-controlled, randomized clinical trial has been completed and the program continues to advance towards commercialization.
